Celldex Therapeutics, Inc. Financing Cash Flow
Celldex Therapeutics, Inc. (CLDX) reported Financing Cash Flow of $324.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $324.66M, a 515228.57% increase year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $327.00K, a 61.88% increase year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.35M, a 249.48% increase year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $774.00K, a 37.53% decline year-over-year.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $2.39M, a 99.46% decline from fiscal 2024.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $441.45M, a 102.07% increase from fiscal 2023.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $218.46M, a 5259.62% increase from fiscal 2022.
- Celldex Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $4.08M, a 98.50% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $324.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $324.98M 10-Q · filed 2026-08-06 | $326.33M derived: sum of 3 quarters · filed 2026-08-06 | $327.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $327.00K 10-Q · filed 2026-05-07 | $1.68M derived: sum of 2 quarters · filed 2026-05-07 | $2.45M derived: sum of 3 quarters · filed 2026-05-07 | $2.51M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.12M derived: sum of 2 quarters · filed 2026-02-25 | $2.19M derived: sum of 3 quarters · filed 2026-08-06 | $2.39M 10-K · filed 2026-02-25 |
| 2025-09-30 | $774.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $837.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.04M 10-Q · filed 2025-11-10 | $1.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $265.00K 10-Q · filed 2026-08-06 | $651.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $202.00K 10-Q · filed 2026-05-07 | $588.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.83M derived: sum of 3 quarters · filed 2026-05-07 | $5.54M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $386.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.63M derived: sum of 2 quarters · filed 2026-02-25 | $5.34M derived: sum of 3 quarters · filed 2026-02-25 | $441.45M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.95M derived: sum of 2 quarters · filed 2025-11-10 | $441.06M 10-Q · filed 2025-11-10 | $658.44M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $439.82M 10-Q · filed 2025-08-07 | $657.20M derived: sum of 3 quarters · filed 2026-02-25 | $657.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $436.11M 10-Q · filed 2025-05-08 | $653.49M derived: sum of 2 quarters · filed 2026-02-25 | $653.74M derived: sum of 3 quarters · filed 2026-02-25 | $653.88M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $217.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $217.63M derived: sum of 2 quarters · filed 2026-02-25 | $217.76M derived: sum of 3 quarters · filed 2026-02-25 | $218.46M 10-K · filed 2026-02-25 |
| 2023-09-30 | $257.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $390.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.08M 10-Q · filed 2024-11-06 | $2.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $827.00K 10-Q · filed 2024-08-08 | $2.22M derived: sum of 3 quarters · filed 2025-02-27 | $4.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $694.00K 10-Q · filed 2024-05-06 | $2.09M derived: sum of 2 quarters · filed 2025-02-27 | $4.39M derived: sum of 3 quarters · filed 2025-02-27 | $4.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.70M derived: sum of 2 quarters · filed 2025-02-27 | $3.77M derived: sum of 3 quarters · filed 2025-02-27 | $4.08M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $2.38M derived: sum of 2 quarters · filed 2023-11-02 | $2.68M 10-Q · filed 2023-11-02 | $3.11M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $375.00K 10-Q · filed 2023-08-08 | $801.00K derived: sum of 3 quarters · filed 2024-02-26 | $272.70M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $304.00K 10-Q · filed 2023-05-04 | $730.00K derived: sum of 2 quarters · filed 2024-02-26 | $272.63M derived: sum of 3 quarters · filed 2024-02-26 | $272.60M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $272.32M derived: sum of 2 quarters · filed 2024-02-26 | $272.30M derived: sum of 3 quarters · filed 2024-02-26 | $272.37M 10-K · filed 2024-02-26 |
| 2021-09-30 | $271.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $271.87M derived: sum of 2 quarters · filed 2022-11-09 | $271.95M 10-Q · filed 2022-11-09 | $271.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $49.00K 10-Q · filed 2022-08-08 | $93.00K derived: sum of 3 quarters · filed 2023-02-28 | $4.58M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $74.00K 10-Q · filed 2022-05-05 | $118.00K derived: sum of 2 quarters · filed 2023-02-28 | $4.61M derived: sum of 3 quarters · filed 2023-02-28 | $169.66M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $4.54M derived: sum of 2 quarters · filed 2023-02-28 | $169.59M derived: sum of 3 quarters · filed 2023-02-28 | $171.23M 10-K · filed 2023-02-28 |
| 2020-09-30 | $4.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $169.54M derived: sum of 2 quarters · filed 2021-11-09 | $171.18M 10-Q · filed 2021-11-09 | $173.60M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $165.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $166.69M 10-Q · filed 2021-08-05 | $169.11M derived: sum of 3 quarters · filed 2022-02-28 | $171.58M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.64M 10-Q · filed 2021-05-06 | $4.06M derived: sum of 2 quarters · filed 2022-02-28 | $6.52M derived: sum of 3 quarters · filed 2022-02-28 | $13.73M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $4.88M derived: sum of 2 quarters · filed 2022-02-28 | $12.10M derived: sum of 3 quarters · filed 2022-02-28 | $16.26M 10-K · filed 2022-02-28 |
| 2019-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $9.68M derived: sum of 2 quarters · filed 2020-11-05 | $13.84M 10-Q · filed 2020-11-05 | $17.40M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-06-30 | $7.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $11.37M 10-Q · filed 2020-08-06 | $14.94M derived: sum of 3 quarters · filed 2021-03-29 | $20.48M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-03-31 | $4.16M 10-Q · filed 2020-05-06 | $7.73M derived: sum of 2 quarters · filed 2021-03-29 | $13.27M derived: sum of 3 quarters · filed 2021-03-29 | $21.54M derived: sum of 4 quarters · filed 2021-03-29 |
| 2018-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $9.11M derived: sum of 2 quarters · filed 2021-03-29 | $17.38M derived: sum of 3 quarters · filed 2021-03-29 | $29.44M 10-K · filed 2021-03-29 |
| 2018-09-30 | $5.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $13.81M derived: sum of 2 quarters · filed 2019-11-12 | $25.87M 10-Q · filed 2019-11-12 | $44.33M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $8.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $20.33M 10-Q · filed 2019-08-07 | $38.79M derived: sum of 3 quarters · filed 2020-03-26 | $50.06M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $12.06M 10-Q · filed 2019-05-07 | $30.52M derived: sum of 2 quarters · filed 2020-03-26 | $41.79M derived: sum of 3 quarters · filed 2020-03-26 | $50.46M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $18.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $29.73M derived: sum of 2 quarters · filed 2020-03-26 | $38.39M derived: sum of 3 quarters · filed 2020-03-26 | $51.29M 10-K · filed 2020-03-26 |
| 2017-09-30 | $11.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $19.94M derived: sum of 2 quarters · filed 2018-11-07 | $32.83M 10-Q · filed 2018-11-07 | $36.12M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $8.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $21.57M 10-Q · filed 2018-08-08 | $24.85M derived: sum of 3 quarters · filed 2019-03-07 | $33.15M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $12.90M 10-Q · filed 2018-05-10 | $16.18M derived: sum of 2 quarters · filed 2019-03-07 | $24.48M derived: sum of 3 quarters · filed 2019-03-07 | |
| 2016-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $11.58M derived: sum of 2 quarters · filed 2019-03-07 | $14.48M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $8.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $11.20M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $2.90M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $193.15M 10-K · filed 2018-03-07 | |||
| 2011-06-30 | $28.33M 10-Q · filed 2011-08-04 | |||
| 2010-06-30 | $522.00K 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |